PA8K PAION AG

EQS-News: PAION AG: Sale of the business operations

EQS-News: PAION AG / Key word(s): Miscellaneous
PAION AG: Sale of the business operations

22.12.2023 / 16:33 CET/CEST
The issuer is solely responsible for the content of this announcement.


PAION AG: Sale of the business operations

 

Aachen (Germany), 22 December 2023 - The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, PA8) announces that PAION AG and its German subsidiary, PAION Deutschland GmbH, with the approval of the preliminary insolvency administrator of PAION AG and PAION Deutschland GmbH, attorney Dr. Mark Boddenberg, today concluded negotiations with HumanWell Healthcare Group ("Humanwell") and entered into an agreement on the sale of the essential business operations of PAION AG and PAION Deutschland GmbH.

The M&A process (fire sale), in cooperation with the M&A consultancy Falkensteg (Düsseldorf) and the provisional insolvency administrator Dr. Mark Boddenberg (Eckert Rechtsanwälte), was successfully concluded as part of a bidding process.

The proceeds from the sale will go to the insolvency estates of the two companies. PAION AG and PAION GmbH will be wound up as part of the insolvency proceedings; shareholders of PAION AG are not expected to receive any payments.

Tilmann Bur, CEO of PAION AG, commented as follows: "It fills us with great satisfaction to know that the core of our company and its products are being placed in competent hands. This ensures that patients can continue to benefit from high-quality therapy options. We also owe this to the dedicated efforts of our employees and the cooperative support of our partners."

The provisional insolvency administrator, lawyer Dr. Mark Boddenberg, who was appointed by Aachen Local Court, added: "The sale will ensure that numerous jobs are preserved. I would like to thank everyone involved for their commitment and professional cooperation, without which this deal would not have been possible."

An exclusive remimazolam license agreement for the Chinese market had been in place between Humanwell, via its subsidiary Yichang Humanwell, and PAION since 2012. In 2022, an agreement on the assignment of patent rights was concluded with Humanwell. Under this agreement, PAION transferred all Chinese remimazolam patents and related future royalties for sales in China to Humanwell.

 

About Humanwell

Humanwell Healthcare (Group) Co. Ltd. is a leading listed Chinese pharmaceutical company mainly engaged in the development, manufacture and distribution of drugs in the fields of anesthesia and analgesics, gynecological diseases, central nervous system, dermatology and respiratory diseases as well as other drugs used in hospitals. Humanwell has more than 520 approved drugs worldwide and 350 drug candidates in the pipeline. In 2022, Humanwell generated sales of USD 3.4 billion and a net profit of USD 0.38 billion. Humanwell distributes its products mainly in China, Africa and the USA and exports its products to more than 50 countries.

 

PAION contact:

Ralf Penner

SVP Investor Relations & Corporate Communications

PAION AG

Heussstrasse 25

52078 Aachen – Germany

Phone 2

E-mail

 

 



22.12.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: PAION AG
Heussstraße 25
52078 Aachen
Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail:
Internet:
ISIN: DE000A3E5EG5
WKN: A3E5EG
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart, Tradegate Exchange
EQS News ID: 1803473

 
End of News EQS News Service

1803473  22.12.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1803473&application_name=news&site_id=research_pool
EN
22/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PAION AG

 PRESS RELEASE

EQS-News: PAION AG: Sale of the business operations

EQS-News: PAION AG / Key word(s): Miscellaneous PAION AG: Sale of the business operations 22.12.2023 / 16:33 CET/CEST The issuer is solely responsible for the content of this announcement. PAION AG: Sale of the business operations   Aachen (Germany), 22 December 2023 - The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, PA8) announces that PAION AG and its German subsidiary, PAION Deutschland GmbH, with the approval of the preliminary insolvency administrator of PAION AG and PAION Deutschland GmbH, attorney Dr. Mark Boddenberg, today con...

 PRESS RELEASE

EQS-News: PAION AG: Verkauf des Geschäftsbetriebes 

EQS-News: PAION AG / Schlagwort(e): Sonstiges PAION AG: Verkauf des Geschäftsbetriebes  22.12.2023 / 16:33 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PAION AG: Verkauf des Geschäftsbetriebes    Aachen, 22. Dezember 2023 – Das Specialty-Pharma-Unternehmen PAION AG (ISIN DE000A3E5EG5; Frankfurter Wertpapierbörse, PA8) gibt bekannt, dass die PAION AG und ihre deutsche Tochtergesellschaft, die PAION Deutschland GmbH, mit Zustimmung des vorläufigen Insolvenzverwalters der PAION AG und der PAION Deutschland GmbH, Herrn Rechtsanwalt...

 PRESS RELEASE

EQS-News: PAION AG WECHSELT VOM PRIME STANDARD IN DEN GENERAL STANDARD

EQS-News: PAION AG / Schlagwort(e): Sonstiges PAION AG WECHSELT VOM PRIME STANDARD IN DEN GENERAL STANDARD 22.11.2023 / 16:05 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PAION AG WECHSELT VOM PRIME STANDARD IN DEN GENERAL STANDARD   Aachen, 22. November 2023 – Das Specialty-Pharma-Unternehmen PAION AG (ISIN DE000A3E5EG5; Frankfurter Wertpapierbörse: PA8) gibt bekannt, dass ein Wechsel der Börsennotierung der PAION AG vom Prime Standard in den General Standard des regulierten Marktes der Frankfurter Wertpapierbörse erfolgt. Der ...

 PRESS RELEASE

EQS-News: PAION AG CHANGES FROM PRIME STANDARD TO GENERAL STANDARD

EQS-News: PAION AG / Key word(s): Miscellaneous PAION AG CHANGES FROM PRIME STANDARD TO GENERAL STANDARD 22.11.2023 / 16:05 CET/CEST The issuer is solely responsible for the content of this announcement. PAION AG CHANGES FROM PRIME STANDARD TO GENERAL STANDARD   Aachen, 22. November 2023 - The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange: PA8) announces that the stock exchange listing of PAION AG will be changed from the Prime Standard to the General Standard of the regulated market of the Frankfurt Stock Exchange. The revocation of th...

 PRESS RELEASE

EQS-News: PAION AG SIGNS STRATEGIC COOPERATION AGREEMENT WITH YICHANG ...

EQS-News: PAION AG / Key word(s): Miscellaneous PAION AG SIGNS STRATEGIC COOPERATION AGREEMENT WITH YICHANG HUMANWELL 21.11.2023 / 10:15 CET/CEST The issuer is solely responsible for the content of this announcement. PAION AG SIGNS STRATEGIC COOPERATION AGREEMENT WITH YICHANG HUMANWELL   Aachen, Germany, 21 November 2023 - The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange: PA8) announces the signing of a Memorandum of Understanding ("MOU") on a strategic cooperation with Yichang Humanwell at the China Innovation Conference. The cooperat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch